Farmas USA

Pijus, tenias razon con CLSN.
:))))

CLSN vuelve a cerrar en máximos por segundo día consecutivo, y hoy tras altibajos bastante rarunos, vuelve también, como ayer, a subir en el tramo de las últimas horas.
Volúmen en aumento, RSI y estocástico igual. El MACD parece que empieza a darse la vuelta mostrando compra, y de momento, las manos fuertes no están entrando.

lo que me he perdido hoy...jaja

vaya movimiento de acciones que ha habido!! a ver mañana como se desarrollan los acontecimientos...

yo creo tb como framus, que la guerra será buena, y tan solo hay que esperar, ¿cuanto? yo no tengo prisa, ahí tengo eso metido, tan solo me gustaría bajar mi media, pero para comprar más acciones por el mismo precio, no me gustaría cerrar un día y no tener nada metido dentro por si acaso...

has visto el volumen de la subidita de última hora de GNOM....

edito: nada, he mirado las órdenes de última hora y no salía ningún bloque importante, y al volver a mirar el gráfico, he visto que lo había mirado pero de otro día... :-(

y VVUS q? tb se ha marcado una buena subida hoy...

tb tiene Buyout esta noche.... ;-)

8,48 ARNA en after con 160.000 de volumen

ARNA

Eisai CEO Sees 'Huge' Medical Need for New Diet Drug

Last update: 8/14/2012 3:56:18 PM

By Peter Loftus

Japan's Eisai Co. (ESALY, 4523.TO) will target a "huge unmet medical need" with its plan to begin selling the new diet drug Belviq in the U.S. in early 2013, the company's leader said Tuesday.

Chief Executive Haruo Naito said Eisai will market the drug by aiming to enhance disease awareness, collaborate with patient groups and seek insurance coverage of Belviq.

Obesity is "obviously a huge unmet medical need in this country," Mr. Naito said in an interview Tuesday. "It's a major medical expenditure and social cost."

Eisai obtained rights to market Belviq in the U.S. and certain other countries from Arena Pharmaceuticals Inc. (ARNA), which developed the drug and will manufacture it.

The U.S. Food and Drug Administration approved Belviq in June, marking the first new weight-loss drug in more than a decade. Less than a month later, in July, the FDA approved a second diet drug, Qsymia from Vivus Inc. (VVUS), setting up a competitive race to capture share of what is expected to be a multibillion-dollar market, as obesity rates have soared.

Eisai expects an early 2013 launch of Belviq because it's awaiting a U.S. Drug Enforcement Administration determination on how Belviq will be classified; it's expected to be a DEA "scheduled" drug because of its potential for abuse. A scheduled drug is subject to certain DEA regulations.

Mr. Naito said Eisai already has a sufficient sales and marketing infrastructure in place to promote Belviq. Last week, Arena said Eisai is expected to have a sales force of about 190 representatives to promote Belviq to doctors. An Eisai spokeswoman said the final number hasn't been determined.

Mr. Naito said Eisai won't promote Belviq as a "general antiobesity drug," in contrast to previous diet drugs. He said the drug is intended for "committed patients" who also make an effort to lose weight through diet and exercise.

Mr. Naito said it was too soon to discuss pricing for Belviq, which some analysts have estimated could range from $3 to $4 a day. Cowen's Simos Simeonidis estimates Vivus's new diet drug will cost about $3.50 a day.

These drugs may not get wide insurance reimbursement initially, as insurers assess the costs and benefits. Mr. Naito said Eisai will work to persuade health-care payers that Belviq provides value because it could mitigate medical costs associated with obesity.

"We'll be working very hard to try to have reimbursement possible for Belviq in this country," he said.

Belviq was shown in studies to lead to average weight loss of 3% to 3.7%, and some patients with diabetes lost at least 5% of their weight, according to the FDA. The drug is associated with certain safety risks, including a condition called serotonin syndrome and disturbances in attention or memory. The FDA required post-marketing studies to assess potential cardiovascular risks of the drug.

Some analysts view Vivus's Qsymia as being more efficacious than Belviq, and it's likely to hit the market first, in the fourth quarter of this year. An Eisai spokeswoman said the company couldn't comment specifically on the competitive landscape, but said the drugs have different target audiences.

Mr. Naito was speaking by phone from a ceremony to open a new manufacturing plant outside Philadelphia by Eisai's Morphotek unit. The plant will supply biologic-based drugs for early-stage clinical trials.

Eisai acquired Morphotek in 2007 for about $325 million. Morphotek is conducting a late-stage clinical trial of an experimental ovarian cancer drug, farletuzumab, and studying other potential new drugs, said Morphotek CEO Nicholas Nicolaides.

____________________________
EDITO

sale a la venta en EEUU sobre 2013, EISAI ve claro ya las ventas que van a tener, calculan unos 3/4 $ al día de gasto de medicamento quien lo tome... si solo faltan los $$$$$$$$$$$$$$$$$$$ en nuestras cuentas yaaa!! Go ARNA Go!!

Yo he vendido es After Market la mitad de mi corto es decir 5000 aun conservo 5000 da dolor venderlo cuando no hay casi liquidez, de hoy a manana no creo suba 100% pasare la noche con ella y a pensar.